CompletedNCT00277654
Risperidone or placebo for bipolarity with panic or generalized anxiety
About this title
Study of Risperidone Monotherapy in Ambulatory Bipolar Disorder With Concurrent Moderately Severe Anxiety and Lifetime Panic or Generalized Anxiety Disorder
Read the official source — NCT00277654Medication studyAges 18+United States
Understand this study
Who was this study for?
Listed age limits: from 18 years.
- Listed locations
- CincinnatiSee all locations and recruitment
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
Study information
Study start dateFebruary 2004
- Recruitment status
- Completed
- Enrollment listed in the registry
- 111
- Sponsor
- Lindner Center of HOPE
- Sponsor type
- Unknown or unclear
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
- Locations
- United States
- Age range
- Over 18 Years
- Official registry ID
- NCT00277654
- Official title
Show the full official title
A Randomized, Double-Blind, Placebo-Controlled Study of Risperidone Monotherapy in Ambulatory Bipolar Disorder With Concurrent Moderately Severe Anxiety and Lifetime Panic or Generalized Anxiety Disorder
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Cincinnati
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is Lindner Center of HOPE.
Did this study involve medication?
Yes. The study involved medication, including Risperidone.
Who was this study for?
Listed age limits: from 18 years.
